GSK’s Trelegy Ellipta (Fluticasone Furoate/Umeclidinium/Vilanterol ‘FF/UMEC/VI’) Receives Expanded Level Approval from EU for COPD

 GSK’s Trelegy Ellipta (Fluticasone Furoate/Umeclidinium/Vilanterol ‘FF/UMEC/VI’) Receives Expanded Level Approval from EU for COPD

Shots:

  • The IMPACT study involves assessing of Trelegy Ellipta (qd,100/62.5/25mcg) vs (ICS/LABA Relvar/Breo Ellipta (FF/VI)) (100/25mcg) & ((LAMA)/LABA Anoro Ellipta (UMEC/VI)) (62.5/25mcg) in patients with COPD
  • The Expanded label approval will serve as a maintenance treatment for patients with moderate-to-severe COPD and shown effective results in comparison to ICS, LABA & LAMA. In 2017, Trelegy Ellipta has also received EU approval for this indication
  • Trelegy Ellipta is a novel triple therapy inhaler, with combination of three molecules and is approved in US for airflow obstruction in patients with COPD, including chronic bronchitis and emphysema

Click here to read full press release/ article | Ref: GSK | Image: Leitbetriebe

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post